Shockwave Medical’s High Stakes: The Cost of a Collapsed Johnson & Johnson Merger
Company Announcements

Shockwave Medical’s High Stakes: The Cost of a Collapsed Johnson & Johnson Merger

Shockwave Medical (SWAV) has disclosed a new risk, in the Corporate Activity and Growth category.

Shockwave Medical faces significant business risk if the proposed Merger with Johnson & Johnson fails to materialize. Conditions outside of Shockwave Medical’s control, such as regulatory approvals and antitrust clearances, are critical to the Merger’s completion. Failure could lead to a substantial drop in share price, a hefty $448.0 million termination fee, and potential reputational damage. The company’s relationships and financial health may suffer, with no guarantee of recovery to pre-announcement stability.

Overall, Wall Street has a Hold consensus rating on SWAV stock based on 2 Buys, 1 Sell and 8 Holds.

To learn more about Shockwave Medical’s risk factors, click here.

Related Articles
Ryan AdistSWAV Upcoming Earnings Report: What to Expect?
TheFlyJohnson & Johnson price target lowered to $180 from $185 at Citi
TheFlySarepta to replace ShockWave Medical in S&P 400 at open on 6/3
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App